Self-Amplifying RNA Cancer Immunotherapy Platforms Market
Key Insight
FMI opines the self-amplifying RNA cancer immunotherapy platforms market was valued at USD 94.0 million in 2025. The industry is expected to cross USD 112.0 million in 2026 and USD 643.2 million by 2036. Personalized neoantigen saRNA platforms is poised to lead by Platform type with 42.6% share in 2026, and Lipid nanoparticle (LNP)-based delivery is estimated to dominate by Delivery system through 2036.